Apoptotic protein expression in favorable-histology Wilms tumor correlates with tumor recurrence

Pediatric Surgery International

Volumn 27, Issue 3, 2011, Pages 303-308

  Agarwal, Shipra ^a   Iyer, Venkateswaran K ^a   Agarwala, Sandeep ^a   Mathur, Sandeep R ^a   Aron, Manju ^a   Datta Gupta, S ^a   Verma, Kusum ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Apoptotic proteins; Favorable histology; Histology; Immunohistochemistry; Recurrence; Wilms tumor

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53;

APOPTOSIS; ARTICLE; BLASTEMA; CANCER PATIENT; CHILD; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEPHROBLASTOMA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR RECURRENCE;

APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; WILMS TUMOR;

EID: 79954445184     PISSN: 01790358     EISSN: 14379813     Source Type: Journal    
DOI: 10.1007/s00383-010-2740-0     Document Type: Article

References (27)

1. E Matsunaga 1981 Genetics of Wilms' tumor Hum Genet 57 231 246 1:STN:280:DyaL3M3jvValsw%3D%3D 10.1007/BF00278936 6265341 (Pubitemid 11121069)
2. JB Beckwith 1997 New developments in the pathology of Wilms' tumor Cancer Invest 15 153 162 1:STN:280:DyaK2s3kvFejtA%3D%3D 10.3109/07357909709115768 9095211 (Pubitemid 27145804)
3. NE Breslow SS Ou JB Beckwith, et al. 2004 Doxorubicin for favorable histology, stage II-III Wilms' tumor: results from the National Wilms' Tumor Studies Cancer 101 1072 1080 1:CAS:528:DC%2BD2cXnvVGis7o%3D 10.1002/cncr.20433 15329918 (Pubitemid 39100443)
4. J de Kraker N Graf H van Tinteren, et al. 2004 Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial Lancet 364 1229 1235 10.1016/S0140-6736(04)17139-0 15464183 (Pubitemid 39311343)
5. DM Green NE Breslow JB Beckwith, et al. 1998 Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group J Clin Oncol 16 237 245 1:CAS:528:DyaK1cXmsVGrug%3D%3D 9440748 (Pubitemid 28041604)
6. DA Hill TD Shear T Liu, et al. 2003 Clinical and biologic significance of nuclear unrest in Wilms' tumor Cancer 97 2318 2326 10.1002/cncr.11325 12712489 (Pubitemid 36444078)
7. N Bardeesy D Falkoff MJ Petruzzi, et al. 1994 Anaplastic Wilms' tumor, a subtype displaying poor prognosis, harbors p53 gene mutations Nat Genet 7 91 97 1:CAS:528:DyaK2cXktlaitbk%3D 10.1038/ng0594-91 8075648
8. N Bardeesy JB Beckwith J Pelletier 1995 Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations Cancer Res 55 215 219 1:CAS:528:DyaK2MXjtFyjsrc%3D 7812946
9. G Basta-Jovanović V Radonjic I Stolic, et al. 2005 Significance of proto-oncogene Bcl-XS/L expression in Wilms tumor Ren Fail 27 13 18 15717629 (Pubitemid 40180102)
10. MF D'Angelo SJ Kausik TJ Sebo, et al. 2003 p53 immunopositivity in histologically favorable Wilms' tumor is not related to stage at presentation or to biological aggression J Urol 169 1815 1817 10.1097/01.ju.0000061963.54213.84 12686851 (Pubitemid 36443516)
11. MA Ghanem TH Van der Kwsat JC Den Hollander, et al. 2001 The prognostic significance of apoptosis-associated proteins bcl-2, bax and bcl-x in clinical nephroblastoma Br J Cancer 85 10 1557 1563 1:CAS:528:DC%2BD38XkslelsA%3D%3D 10.1054/bjoc.2001.2146 11720445 (Pubitemid 34001590)
12. J Huang SZ Soffer ES Kim, et al. 2002 p53 accumulation in favorable histology Wilms' tumor to be associated with angiogenesis and clinically aggressive disease J Pediatr Surg 37 3 523 527 10.1053/jpsu.2002.30858 11877681 (Pubitemid 34188187)
13. C Lahoti P Thorner D Malkin H Yeger 1996 Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome Am J Pathol 148 5 1577 1589 1:STN:280:DyaK283gvVWgsQ%3D%3D 8623926 (Pubitemid 26135898)
14. NR Lemoine CM Hughes JK Cowell 1992 Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumor J Pathol 168 237 242 1:STN:280:DyaK3s%2FpsV2ltw%3D%3D 10.1002/path.1711680213 1334142
15. MW Mayo CY Wang SS Drouin, et al. 1999 WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene EMBO J 18 14 3990 4003 1:CAS:528:DyaK1MXkvV2is78%3D 10.1093/emboj/18.14.3990 10406804 (Pubitemid 29335852)
16. GG Re DJ Hazen-Martin R Bahtimi, et al. 1999 Prognostic significance of bcl-2 in Wilms' tumor and oncogenic potential of bcl-xL in rare tumor cases Int J Cancer 84 192 200 1:CAS:528:DyaK1MXitlCru7c%3D 10.1002/(SICI)1097- 0215(19990420)84:2<192::AID-IJC17>3.0.CO;2-1 10096254 (Pubitemid 29133832)
17. V Schumacher S Schuhen S Sonner, et al. 2003 Two molecular subgroups of Wilms' tumors with or without WT1 mutations Clin Cancer Res 9 2005 2014 1:CAS:528:DC%2BD3sXksVWqtbo%3D 12796362 (Pubitemid 36687619)
18. G Skotnicka-Klonowicz J Kobos E Los, et al. 2001 Prognostic value of p53 expression in Wilms' tumor in children Med Sci Monit 7 6 1224 1229 1:CAS:528:DC%2BD38Xhslamtw%3D%3D 11687734 (Pubitemid 33134655)
19. K Tanaka C Granata Y Wang, et al. 1999 Apoptosis and bcl-2 oncogene expression in Wilms' tumor Pediatr Surg Int 14 243 246 10.1007/s003830050567 (Pubitemid 29257712)
20. JS Dome CA Cotton EJ Perlman, et al. 2006 Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study J Clin Oncol 24 15 2352 2358 10.1200/JCO.2005.04.7852 16710034 (Pubitemid 46630667)
21. HL Neville ML Ritchey 2000 Wilms' tumor: overview of national Wilms' tumor study group results Ped Urol Oncol 27 3 435 442 1:STN:280: DC%2BD3cvmtV2isg%3D%3D (Pubitemid 30655702)
22. H Reinhard O Semler D Bürger, et al. 2004 Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms tumor Klin Padiatr 216 3 132 140 1:STN:280: DC%2BD2c3ns1Kqsg%3D%3D 10.1055/s-2004-822625 15175957 (Pubitemid 38797639)
23. PE Grundy NE Breslow S Li E Perlman JB Beckwith ML Ritchey RC Shamberger GM Haase GJ D'Angio M Donaldson MJ Coppes M Mologolowkin P Shearer PRM Thomas R Macklis G Tomlinson V Huff DM Green 2005 Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable histology Wilms' tumor. A report from the National Wilms' Tumor Study Group J Clin Oncol 23 7312 7321 1:CAS:528:DC%2BD2MXhtF2nsLrN 10.1200/JCO.2005.01.2799 16129848 (Pubitemid 46205952)
24. JC Reed 1994 Bcl-2 and the regulation of programmed cell death J Cell Biol 124 1 6 1:CAS:528:DyaK2cXntl2mtA%3D%3D 10.1083/jcb.124.1.1 8294493 (Pubitemid 24054605)
25. JFR Kerr CM Winterford BV Harmon 1994 Apoptosis. Its significance in cancer and cancer therapy Cancer 73 2013 2026 1:CAS:528:DyaK2cXksl2lt70%3D 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J 8156506 (Pubitemid 24107952)
26. E Yang SK Korsmeyer 1996 Molecular thanatopsis: a discourse on the bcl-2 family and cell death Blood 88 386 401 1:CAS:528:DyaK28XktFSrtLc%3D 8695785 (Pubitemid 26240369)
27. MA Miller B Karacay NE Breslow, et al. 2005 Prognostic value of quantifying apoptosis factor expression in favorable histology Wilms tumors J Pediatr Hematol Oncol 27 1 11 14 10.1097/01.mph.0000149961.71266.27 15654272 (Pubitemid 40175955)